Total Credits: .75 including .75 AMA PRA Category 1 Credit(s)™, .75 AOA Category 1-A Credit(s)
*** Please note this webinar will also be found as part of the 3.25-Credit program Common Diseases & Disorders & Viruses. If you have already completed Common Diseases & Disorders & Viruses, you will not want to choose this program. If you want to learn more about Common Diseases & Disorders & Viruses, choose “Media Types” above and select “Classroom.” ***
COVID-19 is a world health crisis with social and scientific dimensions. It is now recognized that the majority of morbidity and mortality mediated by SAS CoV2 is via immune dysregulation. A series of immune breakthroughs have helped us understand the threat of COVID-19, and this presentation will break them down for a non-immunology audience.
• To describe the natural history and immunobiology of COVID-19
• To describe what tricks SARAS CoV 2 uses to evade the immune response
• To appraise the data on the role of immune-based therapies and vaccines in the defense against COVID-19
The Missouri Association of Osteopathic Physicians and Surgeons (MAOPS) is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. MAOPS designates this program for a maximum of .75 AOA Category 1-A Credits and will report CME and specialty credits commensurate with the extent of the physician's participation.
Missouri Association of Osteopathic Physicians and Surgeons (MAOPS) designates this enduring activity for a maximum of .75 AMA PRA Category 1 Creditsä. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Missouri Association of Osteopathic Physicians and Surgeons (MAOPS) and Kansas City University College of Osteopathic Medicine. MAOPS is accredited by the ACCME to provide continuing medical education for physicians.
None of the planners for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Grievance Policy for AOA Credit:
All grievances should be in writing and should specify the nature of the grievance. Initially, all grievances should be directed to MAOPS Executive Director, who will then forward said grievance to the Education & Convention Committee. All grievances will receive an initial response in writing within 30 days of receipt. If the participant does not receive a satisfactory response, they can submit a complaint in writing to the Council on Continuing Medical Education of the AOA at 142 East Ontario Street, Chicago, IL 60611.
|COVID-19 at One Year (6.89 MB)||49 Pages||Available after Purchase|
Leonard Calabrese, DO, is a Professor of Medicine, Vice Chair of the Cleveland Clinic’s Department of Rheumatic and Immunologic Diseases and the Co-director of the Centre for Vasculitis Care and Research. He also serves as Director of the RJ Fasenmyer Centre for Clinical Immunology at the Cleveland Clinic. He also holds appointments in the Department of Infectious Diseases and the Wellness Institute.
He has particular clinical and research interests in vascular inflammatory disease of the central nervous system, primary and secondary immunodeficiency states and the intersection of infections and autoimmunity. He serves as the editor of Healio Rheumatology and for over past 20 years has developed innovative programs to teach basic, clinical and translational immunology to care providers of patients with immune mediated inflammatory diseases. Over the course of his academic research career, Professor Calabrese has authored over 400 publications including book chapters and peer-reviewed journal articles.
Leonard Calbrese, DO, discloses that he is a paid consultant for Genentech, Glaxo Smith Kline, AbbVie, UCB, Jannsen and Bristol Myers Squibb.
Dr. Calabrese can be reached at email@example.com.